In the present study, the investigators will evaluate the efficacy, toxicities, and of online adaptive radiation therapy (ART) for patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
A dose of 45Gy will be delivered to planning target volume (PTV)
Acute toxicities(CTCA
evaluated with Common Terminology Criteria for Adverse Events (CTCAE) 5.0
Time frame: 3 months for the start of treatment
Response rate after surgery
Clinical and pathological complete response and partial response rate after chemoradiotherapy
Time frame: 3 monsh after treatment
Chronic toxicity
evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme
Time frame: 2 years after treatment
Dose coverage of target volume (assessed by planing target volume V100%)
Planing target volume V100%, defined as the planing target volume receiving at least 100% of the prescribed dose (V100%), is used to evaluate the dose coverage of target volume.
Time frame: Through study completion, an average of five month
Margins for clinical target volume(CTV) and gross tumor volume (GTV)
Margins needed in online ART for CTV to planning clinical target volume (PCTV) and GTV to planning gross tumor volume (PGTV) to cover inter/intra-fraction motion
Time frame: Through study completion, an average of five month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.